Insomnia ziprasidone

Published and unpublished studies from 1995 to 2004, in which intramuscular ziprasidone was assessed, have been reviewed (9). The most common adverse events in the 921 patients were nausea, headache, dizziness, anxiety, somnolence, insomnia, and injection-site pain 1.1 to 6.1% withdrew because of treatment-related adverse events. 

Ziprasidone 10-20 mg twice daily may titrate every Nausea, restlessness, insomnia. 

Observational studies Numerous open studies of ziprasidone promoted by Pfeer, the marketing authorization holder, have previously been published [SEDA-32, 111] and further studies, similarly promoted, have emerged. Of 185 subjects who were switched from olanzapine or risperidone to ziprasidone, 72 completed a 1-year extension study [136 ]. The most common adverse effects were insomnia (23%) and somnolence (11%) no patient had a corrected QT interval over 500 ms at any time during the study. 

---